A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Adult Female Patients with Von Willebrand Disease (VWD) (HMBeacon)

Principal Investigator

Dr Nicola Curry

Contact us

Email: christopher.deane@ouh.nhs.uk

IRAS number

1013589